Kamada (NASDAQ:KMDA) Upgraded at Sidoti

Kamada (NASDAQ:KMDA - Get Free Report) was upgraded by Sidoti to a "hold" rating in a note issued to investors on Thursday,Zacks.com reports.

Several other equities analysts have also issued reports on the company. StockNews.com lowered Kamada from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, March 25th. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Kamada in a report on Thursday, March 6th. Finally, Benchmark started coverage on Kamada in a report on Friday, March 21st. They set a "buy" rating and a $15.00 price objective for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $14.67.

Kamada Trading Up 0.6%

Kamada stock traded up $0.04 during trading hours on Thursday, reaching $6.86. 17,978 shares of the company were exchanged, compared to its average volume of 86,831. The firm has a market cap of $394.31 million, a price-to-earnings ratio of 24.50, a PEG ratio of 0.97 and a beta of 0.94. Kamada has a 12 month low of $4.74 and a 12 month high of $9.16. The stock has a 50-day moving average of $6.62 and a 200 day moving average of $6.57.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Huntleigh Advisors Inc. purchased a new position in shares of Kamada in the 1st quarter worth $863,000. NewEdge Advisors LLC raised its position in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after purchasing an additional 8,260 shares during the period. Aristides Capital LLC increased its position in shares of Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after acquiring an additional 6,850 shares during the period. Geode Capital Management LLC boosted its position in Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after acquiring an additional 1,549 shares in the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in shares of Kamada in the 4th quarter valued at about $67,000. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.